Arcus Biosciences
RCUS
Market cap $1.62B

17.74 USD

+0.27

1.55%

At close Oct 9, 4:00 PM EDT

1 day

1.55%

5 days

16.79%

1 month

8.77%

3 months

25.99%

6 months

1.66%

Year to date

-9.86%

1 year

8.10%

5 years

122.58%

About: Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Employees: 577

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

105% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 21

55% more call options, than puts

Call options by funds: $3.58M | Put options by funds: $2.31M

13% more funds holding

Funds holding: 170 [Q1] → 192 (+22) [Q2]

2% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 62

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

1.9% less ownership

Funds ownership: 59.02% [Q1] → 57.12% (-1.9%) [Q2]

22% less capital invested

Capital invested by funds: $1.01B [Q1] → $791M (-$221M) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$23

30%

upside

Avg. target

$28

58%

upside

High target

$30

69%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

Wells Fargo Eva Fortea Verdejo 0 / 0 met price target	63%upside $29	Overweight Initiated	8 Oct 2024
Wedbush Robert Driscoll 52% 1-year accuracy 28 / 54 met price target	69%upside $30	Outperform Reiterated	3 Oct 2024
Wedbush Robert Driscoll 52% 1-year accuracy 28 / 54 met price target	69%upside $30	Outperform Reiterated	9 Aug 2024
B of A Securities Jason Zemansky 73% 1-year accuracy 8 / 11 met price target	30%upside $23	Neutral Maintained	9 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about RCUS published over the past 30 days

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 24,100 shares of the Company's common stock at an exercise price per share of $17.47, which was the closing price on October 8, 2024, and.

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced four accepted abstracts at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024, in Barcelona, Spain. The data being presented include a growing body of evidence supporting the potential of casdatifan as a b.

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced a clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate casdatifan (AB521), Arcus's investigational HIF-2a inhibitor, in combination with volrustomig, AstraZeneca's investigational PD-1/CTLA-4 bispecific antibody, in patients wi.

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted five new employees options to purchase a total of 38,600 shares of the Company's common stock at an exercise price per share of $15.71, which was the closing price on September 23, 2024, a.

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Arcus Biosciences develops late-stage immunotherapies, with Domvanalimab and Casdastifan leading the way in targeting large oncology markets. Domvanalimab, a Phase 3 anti-TIGIT antibody for NSCLC and GI cancers, could significantly impact treatment upon approval. Casdastifan is advancing to Phase 3 for renal cell carcinoma and may outperform Merck's Belzutifan.

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 27,800 shares of the Company's common stock at an exercise price per share of $16.31, which was the closing price on September 9, 2024, an.

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported it has obtained a $250 million term loan facility from Hercules Capital, Inc. (NYSE: HTGC), a leader in customized debt financing for companies in life sciences and technology-related markets. The additional capital strengthens Arcus's balance sheet and increases f.

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 21,100 shares of the Company's common stock at an exercise price per share of $18.01, which was the closing price on August 23, 2024, and.

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Wednesday, September 4th, 2024 at 4:55 p.m. ET Location: New York, NY Format: Fireside Chat Cantor Fitzgerald G.

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)

Domvanalimab shows promising results in gastric cancer, with a 56% response rate and median progression-free survival of 12.9 months. Quemlicustat sees progress with Taiho exercising rights in Asia, while etrumadenant shows positive results in colorectal cancer trials. Arcus Biosciences pipeline continues to show potential, but TIGIT failures in the industry pose a significant risk to the company's outlook.

Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)

See News Rankings

Charts implemented using Lightweight Charts™